Pharmaceutical Packaging Editorial
-
Biopharma Outsourcing Will Overcome Tariff Troubles
4/6/2018
Why has the biopharma industry insisted upon dual (or triple) sourcing for materials? Why does Big Pharma perform outsized due diligence on offshore CDMOs and CMOs? Why do we focus on costs of all materials and supply? One reason is so we can calmly weather uncertainties such as the current tariff troubles between the U.S. and China.
-
6 Challenges For BioPharma Packaging
4/2/2018
Whether it’s innovative product-development; the need to operate globally; dealing with aging and unhealthy populations; stopping counterfeiting and theft; or facing un-harmonized serialization … biopharma packaging has its challenges.
-
A View Of Biopharma From Pfizer’s Building 41
3/20/2018
This is the story of a man and a building, and their tracing of decades — and hints of the future — at Pfizer, and indeed the entire biopharma industry.
-
Japan Pharma: Top Tier With Tons Of Opportunity
2/9/2018
Opportunities related to the world’s third largest pharma industry tend to get drowned out by U.S. domestic events, and news from Europe, China, and even India. But if you haven’t been, it’s time to start paying attention to Japan again. There are opportunities for partnering, providing services to Japan Pharma, and for market penetration by foreign biopharma companies.
-
Biopharma’s Technology Scouts: Time To Look At CDMOs, Too?
2/2/2018
We’ve heard stories where service providers bring ideas for innovations to biopharma clients, but get rebuked because of the immediate focus on the bottom line for services. Perhaps sponsors should make a new comparison: Where is innovative, biopharma-applicable new-tech, perhaps already focused on elements of a drug owner’s pipeline, actually cheaper to come by?
-
Hospitals To Serve Up IVs, And Now APIs?
1/24/2018
Outsourced Pharma readers must be scratching your heads over the mass-media reported news splash that Intermountain Healthcare is leading four U.S.-based “health care systems” in a consortium to form a generic drug company. In other words, hospitals are getting into APIs. And this, we are told, will save the world from shortages, while reducing pricing for generic drugs. Let’s just say some questions remain, such as: “How’s that all going to work?”
-
No Prescription For Fake News
1/22/2018
We could never get away with “fake news” here. You’d run us out of town in a New York minute. But here’s some thoughts and historical perspective on this theme swirling around us today.
-
Innovation Envy: Surfing California For Next Biopharma Wave
1/16/2018
If you’re interested in new tech and innovation – including outside of the biopharma space – and enjoy warm weather and coastlines, you won’t help but envy Ravi Kiron. Merck KGaA has given him the job of all jobs. Kiron has became the head of biopharma external innovation at Merck’s EMD Serono, Inc., and tasked with establishing its Silicon Valley Innovation Hub. Try not to be too jealous of Kiron as you’re reading. More jobs like his may be on the way.
-
Our 2018 Outsourcing Outlook: Focus On … Amazon?
12/21/2017
It’s time for our 2018 industry outlook. But don’t worry if you’ve already had your share of forecasts slipped into your stockings. I promise ours brings something different to the prognostication party. And it should help readers to consider carefully what you need to focus on to make it another successful year.
-
Thought Leadership Increases Sales
12/1/2017
According to new research from Edelman (the world’s largest PR firm) and LinkedIn – presented in a webinar I attended – expectations for thought leadership greatly undershoot their actual impacts on demand generation, RFP opportunities, new business opportunities, and increased sales.